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Interleukin-15 shares several functional properties
with interleukin-2, and signals through the b and g
chain of the interleukin-2 receptor as well as through
its own high af®nity a chain. In agreement with the
concept that interleukin-2 plays a key role in type IV
immune responses, we have recently shown that an
IL-2±IgG2b fusion protein potently suppresses Th1-
type delayed type hypersensitivity reaction and Th2-
type allergic sensitization in mice. We have now
compared the in vivo effects of IL-2±IgG2b fusion
protein with those of IL-15±IgG2b fusion protein in
a murine model of Th1-type contact hypersensitivity
reaction. Daily systemic injections of IL-2±IgG2b
fusion protein during the sensitization phase or
application of IL-2±IgG2b fusion protein just 2 h
before and 10 h after antigen challenge signi®cantly
inhibited the contact hypersensitivity ear swelling
response, and this without any overt signs of associ-
ated toxicity. Even local injection of IL-2±IgG2b
fusion protein into the earlobe around the time of
antigen challenge inhibited the ear swelling reaction
signi®cantly. In contrast, neither systemic nor local
injection of the IL-15±IgG2b fusion protein modu-
lated the contact hypersensitivity reaction signi®c-
antly. IL-2±IgG2b but not IL-15±IgG2b fusion
protein reduced migration of antigen-presenting cells
from the skin to local lymph nodes, inhibited the
expression of CD80 and CD86, and induced a sig-
ni®cant higher number of CD4+CD25+ T cells.
Therefore, the IL-2±IgGb fusion protein offers a
powerful tool for suppressing and/or preventing
T-cell-mediated hypersensitivity reaction in vivo. Key
words: contact hypersensitivity/fusion protein/interleukin-
2/interleukin-15/Th1. J Invest Dermatol 119:370±376,
2002
N
ew, innovative strategies for the suppression of
damaging type IV immune responses, e.g., in
transplant rejection, allergic reaction, or auto-
immune disease, are a current focus in clinical
research. Recently, for example, fusion proteins
(FP) that contain a cytokine coupled to an immunoglobulin
portion have been explored as possible immunotherapeutics in
clinical medicine (Zheng et al, 1995; Chamow and Ashkenazi,
1996; Kunzendorf et al, 1996a, b). The major advantage of
cytokine±immunoglobulin FP is the substantially prolonged serum
half-life of the cytokine tail in vivo as fusion of the Fc part of IgG to
the cytokine tail prevents its rapid renal clearance (Harvill et al,
1996). For example, compared to the 10±30 min half-life of
interleukin-2 (IL-2) in vivo (Donohue et al, 1984), application of
the FP with a half-life of several hours can stabilize serum levels and
prolong in vivo effects.
Previously, we have described the immunosuppressive effects of
a FP that consists of murine IL-2 fused to murine IgG2b on the
delayed type hypersensitivity (DTH) reaction against sheep red
blood cells (Kunzendorf et al, 1996b) and in a Th2 model of allergic
sensitization (RuÈckert et al, 1998). To further investigate the effects
and the mechanisms of systemic immunosuppression, we employed
here a T-cell-dependent model of contact hypersensitivity (CHS)
reaction in mice (Becker and Knop, 1993; Grabbe and Schwarz,
1998; Hofmann et al, 1998) as a subtype of the classical type IV
DTH reaction.
Epidermal immunization, by painting with the low molecular
weight hapten picryl chloride (PCl), induces activation of
epidermal Langerhans cells and dendritic cells (DCs), which leave
the epidermis, enter the local lymph nodes (Kripke et al, 1990;
Mehling et al, 2000), and undergo maturation, resulting in
downregulated antigen uptake but high expression of major
histocompatibility complex (MHC) class II, CD80, and CD86
molecules. In the lymph node, the DCs present the antigen and
induce systemic sensitization of T cells. After a local antigen
challenge with PCl on the earlobes, the elicitation of an ear
swelling response depends on the activation of antigen-speci®c Th1
cells and a complex network of epidermal cytokines and
neurohormones and the migration of these cells into the skin
(Gocinski and Tigelaar, 1990; MuÈller et al, 1995; Luger et al, 1996;
Corsini and Galli, 2000).
The cytokine IL-2 activates T cells, but is also a potent
suppressor of immune responses. Notably, stimulation of T cells
with IL-2 prior to antigen contact induces apoptosis, which inhibits
immune reactions to the antigen (Lenardo, 1991). IL-2 knockout
mice die after several weeks from dramatic T-cell-mediated
autoimmune attacks, which supports the role of IL-2 in maintain-
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ing the homeostasis of the immune system and in controlling and
suppressing T cell activation (Sadlack et al, 1993).
IL-15 exhibits several biologic activities that had previously also
been identi®ed for IL-2 (Bulfone-Paus et al, 1997a; Waldmann and
Tagaya, 1999). This can be explained in part by the fact that the
receptor complexes for IL-15 and IL-2 share two common
subunits, the b and g chain (Tagaya et al, 1996). Like IL-2, IL-15
promotes activation and proliferation of T cells (Bamford et al,
1994; Bulfone-Paus et al, 1997a), as well as their migration
(Wilkinson and Liew, 1995), and cytokine release (Mori et al,
1996). We have previously shown that IL-15 inhibits apoptosis of T
and B cells (Bulfone-Paus et al, 1997b) and keratinocytes (Lindner
et al, 1998; RuÈckert et al, 2000) and that an IL-15±IgG FP potently
stimulates antibody production in a murine Th2 model of
allergic sensitization (RuÈckert et al, 1998). This designates both
IL-2 and IL-15 receptor-mediated signaling as potentially interest-
ing targets for the suppression of immune responses leading to
allergic diseases.
Despite sharing functional activities with IL-2, IL-15 differs from
IL-2 in its broad constitutive or inducible gene transcription pattern
in several cell and tissue types (Tagaya et al, 1996), and in its tightly
controlled secretion (Onu et al, 1997). In addition, IL-15 displays a
range of activities that is not shared by IL-2: most prominent is its
essential role in natural killer and CD8 T cell development
(Waldmann and Tagaya, 1999; Marks-Konczalik et al, 2000). As
IL-15 is also produced in the skin by epidermal keratinocytes, DCs,
and epidermal Langerhans cells (Blauvelt et al, 1996; RuÈckert et al,
2000) it might in¯uence the local activation and migration of T
cells into the skin.
Therefore, we have compared the effects of IL-15±IgG2b FP
(Bulfone-Paus et al, 1997b) and IL-2±IgG2b FP (Kunzendorf et al,
1996b) in an established CHS mouse model, which utilizes PCl as a
hapten (Hofmann et al, 1998). These studies were performed not
only in order to compare the two FPs with respect to their potential
use for clinical immunotherapy, but also to further dissect
functional differences and analogies between IL-2 and IL-15
in vivo (cf. Bulfone-Paus et al, 1997a).
MATERIALS AND METHODS
IL-2±IgG2b and IL-15±IgG2b FP The IL-2±IgG2b and IL-15±IgG2b
FPs were generated as previously described (Kunzendorf et al, 1996b;
Bulfone-Paus et al, 1997b). Functional activity was tested by proliferation
assays with CTLL cells and by enzyme-linked immunosorbent assay
(ELISA) for IL-2 or IL-15 and IgG2b. The receptor-speci®c binding of
the two FPs to T and B cells was determined by ¯uorescence-activated
cell sorter (FACS) staining. The IL-2±IgG2b and IL-15±IgG2b FPs were
biotinylated. Spleen cells were stimulated in RPMI for 48 h with
lipopolysaccharide (LPS; 10 mg per ml; 2 3 106 cells per ml) for
maximal B cell activation or with ConA (10 mg per ml) for the
activation of T cells. 5 3 105 cells were double stained with 1 mg of the
biotinylated IL-2±IgG2b or IL-15±IgG2b FP followed by incubation
with ¯uorescein 5-isothiocyanate (FITC) labeled streptavidin (Sigma,
Steinheim, Germany) to detect FP binding and phycoerythrin-labeled
antibodies to the B cell marker CD45 B220 (Dianova, Hamburg,
Germany) or to the T cell markers CD4 or CD8 (Pharmingen,
Heidelberg, Germany). FACS analysis was performed with a FACScan
(Becton Dickinson). Shown is the double staining for CD4, CD8, and
CD45 B220 on the y axis and the staining with biotinylated FP on the
x axis.
Animals Female C57BL/6 mice, aged 8±10 wk, were obtained from
the breeding facilities of the Free University Berlin. Only mice with all
back skin hair follicles in the resting phase of the hair cycle (telogen)
were used, as we had previously shown that synchronized hair follicle
cycling in mice signi®cantly in¯uences both the sensitization and the
elicitation phase in murine CHS reactions (Hofmann et al, 1998; Paus et
al, 1999).
Sensitization to PCl and elicitation of CHS C57BL/6 mice were
sensitized as described previously (Hofmann et al, 1998) via the shaved
lower back skin by a single painting with 50 ml of 1% (wt/vol) PCl
(2,4,6-trinitrochlorobenzene; Tokyo Kasei, Tokyo, Japan) in acetone:
ethanol (1:3) on day 0; controls were only painted with the diluents. For
the elicitation of the CHS, 1% PCl in olive oil (20 ml) was painted on
both sides of each earlobe on day 5 after sensitization. Ear thickness was
measured with a spring-loaded micrometer (Peacock, Tokyo, Japan)
before and 24, 48, and 72 h after challenge, as described previously
(Hofmann et al, 1998). For each mouse, the ear swelling response was
expressed as the mean increment in thickness above the basal control
value at 24 h. Analysis at 48 and 72 h showed a decline in ear swelling
but added no additional information (i.e., only IL-2±IgG2b could induce
signi®cant suppression compared to positive controls).
The mice were treated with one of the two FPs, consisting of IL-2 or
IL-15 fused to the mouse IgG2b Fc domain. IgG2b was used as it does
not activate the complement cascade, which could result in unspeci®c
cell lyzes and tissue damage (Kunzendorf et al, 1996b; Bulfone-Paus et al,
1997b). To investigate the effects of the FP on different T cell
populations and different sites of the CHS response the FP was injected
intraperitoneally (i.p.) or locally intracutaneously (i.c.) into the ear lobes
at different times.
Mice were treated with i.p. injection of 10 mg IL-2±IgG2b or IL-15±
IgG2b FP in 100 ml NaCl 2 h before sensitization, followed by injections
of the same amount twice daily every 12 h until 10 h after the challenge.
To study the concentration dependence of the treatment, a second group
received i.p. 5 mg of the IL-2±IgG2b FP every 12 h, from 2 h before
sensitization until 10 h after the local antigen challenge. A third group
was injected i.p. with 10 mg of the IL-2±IgG2b FP only twice, 2 h
before and 10 h after the challenge. Group four was anesthetized, and
5 mg IL-2±IgG2b or IL-15±IgG2b FP in 50 ml saline was injected twice
i.c. at the base of both earlobes, 2 h before and 10 h after the antigen
challenge.
Controls were sensitized but left untreated (positive control); a second
control group was left unsensitized but was injected twice daily i.p. with
10 mg FP to determine possible side-effects of the FP (negative control).
To control unspeci®c ear swelling after local injections, mice were
sensitized, anesthetized, and injected with NaCl, or unsensitized mice
were injected with the FP i.c. into the ear basis. Injection of murine
IgG2b alone had no modulating effect on the immune reaction
(Kunzendorf et al, 1996b).
Five mice were used in each group, and each experiment was repeated
at least twice.
Analysis of homing and activation of antigen-presenting cells
(APCs) Mice were painted on the shaved abdomen with 400 ml of
0.35% FITC solution (Sigma) in acetone:dibutylphthalate (1:1) as
previously described (Macatonia et al, 1986). Mice were left either
untreated or injected 30 min before antigen application with the IL-2±
IgG2b or IL-15±IgG2b FP. Twenty-four hours later, the mice were
sacri®ced and their axillary, cervical, and inguinal draining lymph nodes
(DLN) were removed. All DLN from one mouse were pooled and
100,000 cells were analyzed by a two-laser FACS Calibur with standard
®lter equipment for FITC uptake. DCs were stained with APC-labeled
anti-CD11c (a speci®c DC marker in mice) and phycoerythrin-labeled
anti-CD80 and anti-CD86 antibodies (all from Pharmingen, Heidelberg,
Germany). Given is the percentage of total CD11c+ cells or total cells
that are double positive for CD11c and FITC (thus cells that took up
FITC antigen in the skin and migrated to the DLN). Furthermore,
CD11c+ cells positive for FITC that express high CD80 and CD86
(triple ¯uorescence, channel > 102) are given in percent.
Detection of CD4+CD25+ T cells Draining cervical lymph nodes
from PCl-sensitized mice were analyzed in the different groups 48 h
after earlobe antigen challenge for regulatory T cells. Cells were stained
with FITC-labeled anti-CD4 and phycoerythrin-labeled anti-CD25
antibodies (Pharmingen) and analyzed with a two-laser FACS Calibur
with standard ®lter equipment.
Analysis of apoptosis Spleens were taken from sacri®ced mice 48 h
after earlobe antigen challenge for detection of apoptosis. They were
immediately embedded in OCT (Sakura, Tokyo, Japan) and snap-frozen
in liquid nitrogen. Cryosections (7 mm) were stained for apoptotic cells
with the ApopTaq Kit (Oncor, Geithersburg) according to the
manufacturer's instructions and apoptotic cells were counted visually per
microscopic ®eld (20 separate visual ®elds at 400-fold magni®cation).
Statistical analysis Results are presented as mean 6 SD from pooled
data from two to three identical experiments, all of which gave
comparable results. FACS data from one representative experiment are
shown. The Mann±Whitney U test for unpaired samples was used for
the determination of statistical differences (*p = 0.05).
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RESULTS
IL-2±IgG2b FP suppresses CHS reaction in mice In order to
study the FP effects on a model of T-cell-mediated hypersensitivity
response in vivo, we employed a murine Th1 model of CHS
reaction to the hapten PCl. After sensitization, a type IV immune
response was induced by a local antigen challenge on the earlobe,
and ear swelling was measured as an indicator of the resulting
contact dermatitis. Systemic application of 10 mg IL-2±IgG2b FP
every 12 h during the sensitization phase, or 2 h before and 10 h
after antigen challenge, signi®cantly suppressed the CHS reaction (p
= 0.05, Fig 1A). Application of 5 mg FP every 12 h was not
suf®cient to suppress the CHS reaction (Fig 1A). To analyze
possible side-effects of the FP, we injected 10 mg IL-2±IgG2b every
12 h into unsensitized mice. No obvious treatment toxicity was
seen, as the mice showed normal behavior and fur appearance as
well as the absence of overt neurologic or gastrointestinal
abnormalities and weight loss.
To study whether even local administration is effective, the FP
was injected i.c. into the basis of the ear in anesthetized mice. The
local injection of 5 mg IL-2±IgG2b FP or injection of the vehicle
(0.9% NaCl) alone twice within 12 h (total amount 50 ml) did not
induce unspeci®c ear swelling in unsensitized mice 12 h after the
last injection. The injection of 5 mg IL-2±IgG2b FP 2 h before and
10 h after antigen challenge on the ear of sensitized mice, however,
reduced the swelling by almost 50% (p < 0.05) compared to the
positive control (Fig 1B). Unspeci®c effects of the local IL-2 FP
injection, i.e., in¯ammation at the site of injection, were excluded
by immunohistology (not shown).
Application of IL-15±IgG2b FP does not affect CHS ear
swelling In view of the functional similarities and the distinct
bioactivities of IL-2 and IL-15 (see above), we were interested to
learn how an IL-15±IgG2b FP, which differs only in the cytokine
tail from the IL-2±IgG2b FP, affected the CHS reaction. In contrast
to the IL-2 FP, neither systemic application (Fig 2A) nor local
application (Fig 2B) of the IL-15±IgG2b FP signi®cantly altered
the CHS immune response after local antigen challenge on the ear.
The control groups showed the expected results and, again, no
overt treatment toxicity was observed.
IL-2±IgG2b and IL-15±IgG2b bind to activated T and
B cells As a ®rst step to dissecting the underlying mechanisms
of action of the distinct CHS effects of the two FPs, the cellular
targets of each FP were characterized. As both the cytokine and the
IgG2b tail of the FPs are fully functional and bind to the
appropriate receptors on the surface of various cell populations
(Kunzendorf et al, 1996b; Bulfone-Paus et al, 1997b; RuÈckert et al,
2000), the proportion of activated T and B cells to which the FPs
bind was quanti®ed by FACS staining. Nearly all 24 h short-time
ConA-stimulated CD4+ or CD8+ T cells as well as about 90% of
24 h short-time LPS-stimulated B cells bound the IL-2±IgG2b or
IL-15±IgG2b FP [Fig 3A, the percentage of single (left) and double
positive CD4, CD8, or CD45 B220 cells out of all cells (= 100%)
are shown]. Staining of unstimulated cells revealed binding to T
and B cells as well, although the percentage was below 20% (not
shown). Therefore, both T and B cells express functional receptors
for IL-2 and IL-15 FP.
Next we analyzed the biologic activity of the two FP in vitro
(Fig 3B). The proliferation of the IL-2/IL-15 dependent murine
CTLL-2 T cell line was analyzed in an IL-2/IL-15 bioassay by 3H
thymidine incorporation after adding IL-2±IgG2b or IL-15±IgG2b
FP in increasing concentrations from 1.6 ng per ml up to 200 ng
per ml and, as control, a single dose of IL-2 or IL-15 cytokine (5 ng
per ml). Both FPs could induce signi®cant proliferation. The
recombinant cytokines had comparable activity at 5 ng per ml.
These data demonstrate that the differences in the in vivo effects on
CHS ear swelling are not attributable to the (in vitro) biologic
activity of one of the FP, as both FPs strongly induce proliferation
of CTLL-2 cells.
High dose IL-2±IgG2b FP treatment induces splenocyte
apoptosis To better understand whether distinct effects of the
two FPs on T cell apoptosis might underlie the different effects of
the IL-2 FP and the IL-15 FP on CHS modulation, systemic
induction of apoptosis was analyzed by immunohistology in the
spleen. IL-2 reportedly induced apoptosis of T cells when given
prior to antigen restimulation (Lenardo, 1991). Systemic
application of high dose (10 mg) IL-2±IgG2b FP twice a day
during the sensitization period (5 d) indeed very signi®cantly
increased the number of apoptotic cells in the spleen germinal
Figure 1. Systemic and local application of
the IL-2±IgG2b FP inhibits ear swelling
reaction. (A) Systemic injection. The mice were
injected every 12 h with the FP in 100 ml saline.
Negative controls were left unsensitized but were
injected with 10 mg of the IL-2±IgG2b FP every
12 h, but no toxic side-effects and no unspeci®c
in¯uence on ear swelling after PCl challenge was
observed. The positive control was sensitized and
challenged but left untreated. Injection of the IL-2
FP just twice, 2 h before and 10 h after antigen
challenge, signi®cantly inhibited ear swelling
response. Treatment twice a day with a low dose
of 5 mg could not inhibit ear swelling but 10 mg
were suf®cient to suppress the swelling reaction.
(B) Even the local injection of 5 mg IL-2±IgG2b
FP i.c. into the ear basis 2 h before and 10 h after
challenge signi®cantly inhibited the ear swelling
reaction. The local treatment with NaCl or FP
alone induced no unspeci®c reactions, i.e., no
swelling was seen in unsensitized mice, and
injection of the diluents alone could not inhibit
ear swelling in sensitized mice.
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centers of sensitized animals. Without FP treatment 57 6 14
apoptotic cells were seen per visual ®eld in the spleen (40-fold
magni®cation); treatment with 10 mg IL-2 FP increased the
number of apoptotic cells to 102 6 33 per visual ®eld (p
< 0.001), whereas IL-15 FP had no signi®cant effect compared
to the control (42 6 9 cells per visual ®eld).
The induction of apoptosis in our model, however, was only
proven after high dose systemic treatment with the IL-2 FP. The
inhibitory effects of short-term as well as local IL-2 FP treatment on
the exacerbation of the ear swelling reaction seemed also to be
mediated by local inactivation of T cells in the skin and the DLN.
IL-2±IgG2b induces CD4+CD25+ T cells in vivo Several
recent reports have emphasized the importance of so-called
``regulatory T cells'', which are characterized by in vivo
expression of CD4 and CD25 and ef®ciently down-modulate
Figure 3. IL-2±IgG2b and IL-15±IgG2b FPs bind to activated T and B cells and induce CTLL-2 proliferation in vitro. (A) Spleen cell
suspensions were activated for 24 h with 3 mg per ml ConA or 10 mg per ml LPS. After this short-time ConA activation, the cell suspension reached a
percentage of about 27% CD4 T cells, 17% CD8 T cells, and after LPS activation about 70% B cells. T and B cells were double-stained with
phycoerythrin-labeled anti-CD4, anti-CD8, and anti-CD45 B220, and with biotinylated IL-2±IgG2b FP or IL-15±IgG2b FP, followed by FITC-
labeled streptavidin. The upper right quadrant shows the percentage of all (CD4-, CD8-, or CD45 B220-positive) cells in the spleen cell suspension
(total of 100%), which bind the IL-2 or IL-15 FP and the second phenotyping antibody (e.g. double positive); the upper left quadrant shows the
remaining CD4-, CD8-, CD45 B220-positive cells, which do not bind the FP (single positive). (B) IL-2±IgG2b and IL-15±IgG2b FP have comparable
biologic activity in vitro. The murine IL-2/IL-15-dependent T cell line CTLL-2 was incubated for 24 h with the indicated concentrations of FPs or
single cytokine (IL-2, IL-15). 3H thymidine was added for the last 8 h and incorporated radioactivity was analyzed with a liquid scintillation counter.
Given are counts per minute (cpm) 3 103. Shown is one representative out of at least ®ve experiments.
Figure 2. IL-15±IgG2b treatment showed no
signi®cant effect on ear swelling reaction. (A)
Systemic injection of 10 mg IL-15±IgG2b every
12 h did not inhibit ear swelling and had no toxic
effects. Injection of the FP twice, before and after
challenge, as well as treatment every 12 h for 5 d
did not signi®cantly alter the swelling reaction. (B)
Local injection of the IL-15±IgG2b FP as well as
control NaCl injections did not change the ear
swelling level in sensitized mice after antigen
challenge.
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immune responses in vivo and in vitro (for review on the role of
CD4 in CHS response see Gorbachev and Fairchild, 2001).
Therefore we analyzed the induction of these T cells in the local
cervical lymph nodes after IL-2/IL-15 FP treatment, 48 h after
local ear challenge. In negative control mice, 2.1% of all lymph
node cells were CD4+CD25+ (Fig 4). Sensitization and antigen
challenge on the earlobe increased the amount slightly to 2.9%
(increase by 38% compared to negative control). Interestingly, daily
administration of IL-2±IgG2b FP resulted in a signi®cant increase
to 6.8% (increase by 220%), whereas IL-15±IgG2b only slightly
increased the amount of CD4+CD25+ cells to 3.3% (increase by
57%).
To exclude that this increase is solely mediated by short-term
activation of CD4 T cells (which also upregulate CD25), we
performed a FACS analysis also 24 h after i.p. FP injection in
unsensitized mice. As shown in Fig 4 (lower panel), neither the IL-2
FP nor the IL-15 FP could induce a signi®cant increase of
CD4+CD25+ T cells 24 h after i.p. injection compared to the
negative control (2.6%, 2.2%, respectively, compared to 2.1% in
the negative control).
IL-2±IgG2b FP inhibits antigen uptake in the skin and
activation/migration of DCs To better understand the
underlying mechanisms of CHS inhibition in vivo, we ®rst
analyzed the antigen uptake by epidermal Langerhans/DCs and
the migration to the local DLN as well as the expression of B7
costimulatory molecules on DCs, which are critically implicated in
CHS reactions (Xu et al, 1997). The ®rst step in initiating a CHS
response is the antigen uptake in the skin by epidermal Langerhans/
DCs, their migration to the local DLN, and the antigen
presentation to T cells, all of which are steps that are in¯uenced
by IL-2 or IL-15 (Granucci et al, 2001; Ohteki et al, 2001). Thus,
the effects of the two FPs on antigen uptake in the skin were
analyzed by using another hapten, the ¯uorescent dye FITC as
previously described (Macatonia et al, 1986), which can easily be
detected by FACS. The CD11c+ Langerhans/DCs in the skin take
up the antigen and migrate to the DLN, where they present the
antigen to T cells. As shown in Fig 5, the total number of DCs in
DLN (CD11c+) was comparable in all FITC-painted groups [as
well as the total cell number per lymph node (data not shown)].
Negative controls (without FITC painting) showed a lower
number of DCs in the lymph node (2.5%). Single treatment with
IL-2±IgG2b FP, however, reduced the number of FITC-positive
DCs (CD11c+/FITC+) from 57% in untreated mice to 37%. The
IL-15±IgG2b FP had no effect on antigen uptake compared to the
untreated controls. Finally, we analyzed the activation of DCs by
quantifying the expression of the costimulatory molecules CD80
and CD86 (B7.1 and 7.2), which have been shown to play an
important role in CHS reaction (Katayama et al, 1997). IL-2±IgG2b
reduced the expression of both molecules on antigen-bearing cells
(e.g., FITC positive) compared to the untreated, positive control
mice (CD11c/FITC/CD80+, 24% compared to 42% in untreated
FITC-painted mice; CD11c/FITC/CD86+, 39% compared to
61% in untreated FITC-painted mice). IL-15±IgG2b FP had no
modulating effects on CD80/CD86 expression compared to the
non-FP-treated positive controls. For comparison, DCs of
untreated mice were analyzed as negative control, without FITC
¯uorescence (note: no CD11c/FITC cells). These DCs from
normal, untreated mice expressed low levels of CD80 and CD86
(only 5% and 16%, respectively; high expression in channel > 102;
Fig 5, ®rst lane).
DISCUSSION
We have shown here that an IL-2±IgG2b FP potently suppresses a
CHS reaction in mice. It inhibits antigen uptake and activation of
professional APCs, and increases the number of CD4+CD25+ T
cells.
The cytokine IL-2 is an important activator of T and B cells: it
induces and promotes cellular as well as humoral immune responses
(Horak et al, 1995; TheÁze et al, 1996). Evidence from knockout
mice, however, indicates that IL-2 and its receptors play an
important role in controlling the activation program of T cells, to
maintain homeostasis and to prevent autoimmunity. Antigen
receptor restimulation induces apoptosis of T cells when they are
previously exposed to IL-2 (Lenardo, 1991). T cells of CD25 ±/±
mice displayed a failure in undergoing active and passive cell death,
demonstrating the speci®c priming of T cells to undergo apoptosis
by the IL-2 receptor a chain (Van Parijs et al, 1997). Accumulation
of activated, autoreactive T cells in IL-2 ±/± mice is caused by the
failure of T cells from IL-2 ±/± mice to become anergic upon
antigen restimulation and to undergo Fas-induced apoptosis (Kneitz
et al, 1995).
Besides activation-induced apoptosis, another important down-
regulatory mechanism of immune responses is mediated by
regulatory T cells, which are CD4+CD25+ (Shevach, 2000). The
exact mechanism by which these cells downregulate immune
response is not clear yet; cell±cell contact as well as the release of
soluble factors (transforming growth factor b, IL-10) may be
involved. These cells are dependent on IL-2 and are absent in IL-2
knockout mice (Papiernik et al, 1998), which suggests a role for
IL-2 in expansion or generation of these specialized suppressive
cells. Indeed, injection of IL-2±IgG2b FP (but not IL-15±IgG2b
FP) in our CHS model led to a signi®cant expansion of
CD4+CD25+ cells, as analyzed 48 h after antigen challenge.
Short-term activation of T cells by IL-2 is unlikely and cannot
Figure 4. IL-2±IgG2b FP causes signi®cant induction of
CD4+CD25+ T cells. Local draining cervical lymph nodes were
analyzed by FACS for CD4+CD25+ T cells 48 h after antigen challenge
(negative control, without PCl; positive control, PCl sensitization and
challenge; IL-2±IgG2b, PCl sensitization, challenge, and i.p. treatment
with FP; IL-15±IgG2b, PCl sensitization, challenge, and i.p. treatment
with FP). In addition, the effects of the two FPs on CD4+CD25+
regulatory T cells without sensitization were analyzed 24 h after i.p.
injection in vivo. Total lymph node cell suspension was stained with
antibodies against CD4 (coupled to APC) and CD25 (coupled to
phycoerythrin). Given is the absolute percentage of CD4+CD25+
regulatory T cells in the lymph nodes.
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be simply attributed to activation of T cells by IL-2 (as 24 h after FP
injection in unsensitized mice an increase of CD25 by activated T
cells was not detected).
Taken together, results from IL-2 knockout mice, e.g.,
overactivation of T cells, and the results of our study suggest that
IL-2 may play an important role in the suppression of T-cell-
mediated effector functions in vivo, which was demonstrated here
by application of an IL-2±IgG2b FP.
Another important effect was seen on DCs, which express the
IL-2 receptor g as well as the high af®nity a chain (K.B., data not
shown, and Fukao and Koyasu, 2000). IL-2±IgG2b FP could
reduce DC/Langerhans cell antigen uptake and/or their migration
from the skin to the DLN. Furthermore, the expression of
costimulatory molecules CD80 and CD86 was inhibited, whereas
they are normally upregulated after activation by antigen uptake
and are markers of mature, fully active APCs. This reduced
maturation may result in impaired T cell sensitization by driving
antigen-speci®c cells into apoptosis in the absence of costimulation
(Radvanyi et al, 1996). It also has been shown that both CD80 and
CD86 are important in the induction of CHS responses (Katayama
et al, 1997; Rauschmayr-Kopp et al, 1998).
Injection of the IL-15±IgG2b FP ®rst serves as a control for the
speci®city of the suppressive properties seen with the IL-2±IgG2b
FP. That the IL-15±IgG2b FP has a strong in vivo effect was shown
previously, where it could boost and accelerate antibody produc-
tion up to 50-fold in a murine model of allergic sensitization
(RuÈckert et al, 1998). Both FPs showed comparable in vitro
bioactivity; thus the effects are not attributable to different kinetics
or stimulatory properties. As the effects of the two FPs differ in vivo
but the immunoglobulin tails are identical, the effects of the IL-2
FP clearly depend on the cytokine tail. The failure of substitution of
IL-15 using the IL-15±IgG2b FP to affect the CHS reaction may be
explained in part by the very strong antiapoptotic effects of this
cytokine as we have previously shown (Bulfone-Paus et al, 1997b;
Lindner et al, 1998; RuÈckert et al, 2000). These antiapoptotic effects
and the reported T cell activation by IL-15 (Bulfone-Paus et al,
1997a) nevertheless did not result in an ampli®cation of ear
swelling. Blocking of IL-15 and IL-15-de®cient mice show,
however, that IL-15 is essential for mounting a CHS immune
response (RuÈckert et al, manuscript in preparation). The inhibitory
effect of IL-15 blocking in a DTH model (Kim et al, 1998) may be
attributed to the same phenomena. IL-15 is essential in mounting
this DTH immune response; however, the potent pro-in¯amma-
tory action of endogenous IL-15 cannot be increased by treatment
with additional, exogenous IL-15 cytokine or FP.
We here present the ®rst evidence that an IL-2±IgG2b FP after
systemic and local treatment can potently suppress a CHS reaction
in mice. Inhibition of the CHS elicitation phase after only two local
injections of low amounts of IL-2±IgG2b FP in the apparent
absence of obvious systemic side-effects designates this protein as an
attractive new tool for immunosuppression in vivo under circum-
stances where, for example, transplant rejection or autoimmune
reactions are to be suppressed.
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